Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2022-05-25 Notice of Dividend Amou…
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Monday, 6th June, 2022 as the Record Date for taking record of the Members of the Company entitled for the purpose ....
Notice of Dividend Amount Classification · 95% confidence The document is a short notice (1450 characters) addressed to a stock exchange regarding the fixing of a Record Date for shareholders entitled to receive a final dividend for the fiscal year 2021-22. It references Regulation 42 of the SEBI Listing Regulations, which pertains to dividend record dates. The document does not contain financial statements or detailed financial data, nor does it present a report or results. It is an announcement about dividend-related dates and shareholder entitlements. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-05-25 English
Recommended to the members to obtain enabling approval for issuance of Equity Shares including Convertible Bonds/ Debentures through Qualified Institutional Placement (QIP) and / or Depository ....
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding multiple corporate actions and financial results. It mentions the approval of audited financial results for the quarter and year ended 31st March 2022, including standalone and consolidated results with audit reports. It also discusses recommendations for issuance of equity shares through Qualified Institutional Placement (QIP), declaration of dividends, bonus share issuance, and increase in authorized share capital. The document references Regulation 30 and 33 of SEBI Listing Regulations, which pertain to disclosures of financial results and corporate actions. The document includes detailed information about the bonus issue and dividend proposals, and it states that the financial results and audit reports are enclosed as annexures. The length of the document (over 11,000 characters) and the inclusion of substantive financial data and corporate actions indicate this is a comprehensive regulatory disclosure rather than a brief announcement or a simple report publication notice. The primary focus is on the audited financial results and related corporate actions approved by the Board, which aligns with a Capital/Financing Update (CAP) filing, as it includes updates on capital structure changes (bonus shares, QIP) and dividend recommendations. It is not a full Annual Report (10-K), nor a simple earnings release (ER), nor a report publication announcement (RPA). Therefore, the best classification is Capital/Financing Update (CAP).
2022-05-25 English
Board has recommended to the members A final dividend of Rs. 23/- (460%) per equity share of Rs. 5/- each including the special dividend of Rs. 15/~ per equity share.
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding multiple corporate actions and financial results. It mentions the approval of audited financial results for the quarter and year ended 31st March 2022, including standalone and consolidated results with audit reports. It also discusses recommendations for issuance of equity shares through QIP, declaration of dividends, bonus share issuance, and increase in authorized share capital. The document references Regulation 30 and 33 of SEBI Listing Regulations, indicating it is a regulatory disclosure. The content includes detailed information about the bonus issue, dividend, and capital changes, but it is primarily an announcement of these approvals and recommendations rather than the full financial report itself. The document length is about 11,617 characters, which is substantial but the text is structured as a disclosure letter with enclosures mentioned (Annexure A, B, C) rather than the full reports included. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of financial results and corporate actions, not the full Annual Report or standalone Audit Report. It also includes capital change announcements but not detailed financial statements or management discussion sections that would qualify it as an Annual Report or Interim Report.
2022-05-25 English
Disclosure pursuant to Regulation 30 of (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations")
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to SEBI Listing Regulations, dated 25th May 2022, addressed to stock exchanges (BSE and NSE). It announces the Board's approval of audited financial results (standalone and consolidated) for the quarter and year ended 31st March 2022, including audit reports with unmodified opinion. It also includes a press release on financial results, recommendations for issuance of equity shares through QIP, declaration of final dividend, bonus share issue proposal, and increase in authorized share capital. The document contains detailed information on these corporate actions and financial results but is primarily an announcement of these approvals and recommendations rather than the full annual report or the full audited financial statements themselves. The length is about 11,617 characters, which is relatively short for a full Annual Report (10-K). The document is a regulatory disclosure filing under SEBI regulations, reporting financial results and corporate actions. It is not a full Annual Report (10-K), nor a Management Discussion & Analysis (MDA), nor a standalone Audit Report (AR). It is a regulatory announcement of financial results and corporate actions pursuant to listing obligations. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-05-25 English
Press Release
Annual Report Classification · 95% confidence The document is a detailed disclosure pursuant to SEBI Listing Regulations, including audited financial results (standalone and consolidated) for the year ended 31 March 2022, along with audit reports. It also includes information on dividend recommendations, bonus share issuance, and increase in authorized share capital. The presence of an Independent Auditor's Report on the standalone annual financial results further confirms this is a comprehensive annual financial report. The document length is substantial (15,000 characters), and it contains actual financial data and audit opinions, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent) or at least the audited annual financial results filing. Given the Indian context and SEBI regulations, such filings are typically classified as Annual Report (10-K).
2022-05-25 English
Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2022
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a presentation to analysts on the audited financial results for the quarter and year ended 31st March 2022. It includes a summary of revenue figures for Q4 FY22 compared to Q4 FY21. The document is short (1663 characters) and explicitly states it is a presentation to analysts, not the full financial report itself. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not an Annual Report (10-K) or Interim Report (IR) because it is a presentation, not the full report. It is not a Report Publication Announcement (RPA) because it contains actual financial data and summary. Therefore, the correct classification is Investor Presentation (IP).
2022-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.